Loading organizations...
§ Private Profile · Paris, France
Develops handheld LC-OCT medical imaging devices for dermatologists, focused on non-invasive 3D skin tissue visualization for cancer detection.
Based in Paris, France, DAMAE Medical develops handheld medical imaging devices and artificial intelligence software for the non-invasive, real-time 3D visualization of skin tissues. The company's core technology utilizes line-field confocal optical coherence tomography to help dermatologists and hospitals detect, diagnose, and monitor skin cancers without requiring traditional biopsies. Operating with a current workforce of approximately 30 employees, the enterprise also serves the research and evaluation needs of major cosmetic and pharmaceutical companies. The firm has secured over €20 million in total venture investment since its inception, including a €5 million Series A financing round led by BNP Paribas Développement. Additional financial backing has been provided by prominent venture capital entities such as Kurma Partners, Paris Saclay Seed Fund, and Idinvest Partners. DAMAE Medical was founded in 2014 by Anaïs Barut, David Siret, and Arnaud Dubois.
DAMAE Medical has raised $25.5M across 3 funding rounds.
DAMAE Medical has raised $25.5M in total across 3 funding rounds.
DAMAE Medical has raised $25.5M across 3 funding rounds. Most recently, it raised $17.4M Series B in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 26, 2025 | $17.4M Series B | — | BNP Paribas Développement, Ispb, Jean Francois Rivassou | Announced |
| Feb 1, 2022 | $6M Series A | BNP Paribas Développement | AQUITI Gestion, Kurma Partners, Paris Saclay | Announced |
| Apr 27, 2017 | $2.2M Venture Round | — | Idinvest Partners, Kurma Partners, News Invest, Paris Saclay Seed Fund | Announced |
DAMAE Medical has raised $25.5M in total across 3 funding rounds.
DAMAE Medical's investors include BNP Paribas Développement, ISPB, Jean-Francois Rivassou, AQUITI Gestion, Kurma Partners, Paris Saclay, Idinvest Partners, News Invest, Paris Saclay Seed Fund.
DAMAE Medical is a French medtech company developing the deepLive™ imaging system, a handheld device based on line-field confocal optical coherence tomography (LC-OCT) technology for non-invasive, high-resolution 3D imaging of skin lesions at cellular level.[1][2][3] It serves dermatologists, oncologists, and clinicians by reducing unnecessary biopsies—often 70-80% of cases—improving early skin cancer detection (melanoma and non-melanoma), and enabling precise lesion margin assessment for surgery.[1][2][6] With over €22M raised (including €15M Series B in November 2025 led by Creadev), the company has deployed devices in 40+ global centers, backed by 250+ publications, and is integrating AI for diagnostics.[2][3][6]
DAMAE Medical spun out in 2014 from Institut d'Optique Graduate School (Palaiseau, France) by a team of photonics researchers, including Prof. Arnaud Dubois from Charles Fabry Laboratory (CNRS, Institut d’Optique, Université Paris-Saclay).[2][3][6] The idea stemmed from patented LC-OCT technology for biological imaging, adapted into a real-time skin diagnostic device after validating its potential for carcinomas and melanomas in 2015.[2][3] Early milestones included a 2016 clinical demonstrator at Saint-Etienne University Hospital, €2M seed funding in 2017 from Kurma Partners, Idinvest, and others, and a 2019 handheld 3D probe with 10 units produced for validation.[3] Pivotal traction came via EU-funded OCTAV project for market readiness and regulatory approval.[4]
DAMAE rides the AI-medtech wave in dermatology, addressing rising skin cancer incidence (global epidemic) amid biopsy overload and pathologist shortages.[1][6] Timing aligns with non-invasive diagnostics demand, post-COVID telehealth push, and EU/US regulatory nods for optical imaging.[4] Market tailwinds include aging populations, precision oncology, and digital pathology growth; LC-OCT fills the gap between dermoscopy (surface-only) and biopsy (invasive).[2][3] It influences ecosystems by enabling AI training on rich 3D datasets, collaborating with top clinics, and shifting guidelines toward "microscopic imagery-guided" procedures.[2][6]
DAMAE's €15M Series B fuels deepLive™ global rollout, AI enhancements, and surgical integrations, targeting routine clinical adoption and research data monetization.[6] Trends like multimodal AI diagnostics and personalized dermato-oncology will propel it, potentially capturing share in a $10B+ skin cancer market. Influence may evolve to platform leader, powering biopsy-free workflows and reducing healthcare costs—transforming DAMAE from spinout innovator to dermatology standard.[1][2][6]